{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T22:18:13Z","timestamp":1782512293939,"version":"3.54.5"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100010993","name":"Key Laboratory of Bioorganic Chemistry and Molecular Engineering","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010993","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["DUT20LK28"],"award-info":[{"award-number":["DUT20LK28"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["DUT20YG133"],"award-info":[{"award-number":["DUT20YG133"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["DUT21RC(3)090"],"award-info":[{"award-number":["DUT21RC(3)090"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81903462"],"award-info":[{"award-number":["81903462"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82073703"],"award-info":[{"award-number":["82073703"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009007","name":"Guangxi Normal University","doi-asserted-by":"publisher","award":["CMEMR2021-B05"],"award-info":[{"award-number":["CMEMR2021-B05"]}],"id":[{"id":"10.13039\/501100009007","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005047","name":"Liaoning Provincial Natural Science Foundation","doi-asserted-by":"publisher","award":["2021-BS-061"],"award-info":[{"award-number":["2021-BS-061"]}],"id":[{"id":"10.13039\/501100005047","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.bcp.2022.114964","type":"journal-article","created":{"date-parts":[[2022,2,16]],"date-time":"2022-02-16T10:48:37Z","timestamp":1645008517000},"page":"114964","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Bcr-Abl drives the formation of Hsp70\/Bim PPI to stabilize oncogenic clients and prevent cells from undergoing apoptosis"],"prefix":"10.1016","volume":"198","author":[{"given":"Hong","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziqian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwituze","family":"Laura Bonnette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yafei","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qishuang","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhichao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2022.114964_b0005","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/nrc1567","article-title":"Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia","volume":"5","author":"Ren","year":"2005","journal-title":"Nat Rev Cancer."},{"issue":"3","key":"10.1016\/j.bcp.2022.114964_b0010","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/sj.leu.2402060","article-title":"Adult precursor B-ALL with BCR\/ABL gene rearrangements displays a unique immunophenotype based on the pattern of CD10, CD34, CD13 and CD38 expression","volume":"15","author":"Tabernero","year":"2001","journal-title":"Leukemia"},{"key":"10.1016\/j.bcp.2022.114964_b0015","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/nchembio.775","article-title":"BCR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid leukemia","volume":"8","author":"Hantschel","year":"2012","journal-title":"Nat Chem Biol."},{"key":"10.1016\/j.bcp.2022.114964_b0020","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1038\/leu.2009.49","article-title":"Bcr-Abl-mediated redox regulation of the PI3K\/AKT pathway","volume":"23","author":"Naughton","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.bcp.2022.114964_b0025","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med."},{"key":"10.1016\/j.bcp.2022.114964_b0030","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1182\/blood-2004-08-3097","article-title":"The development of imatinib as a therapeutic agent for chronic myeloid leukemia","volume":"105","author":"Michael","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2022.114964_b0035","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1038\/sj.leu.2402741","article-title":"Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy","volume":"16","author":"Hochhaus","year":"2002","journal-title":"Leukemia"},{"key":"10.1016\/j.bcp.2022.114964_b0040","doi-asserted-by":"crossref","first-page":"939","DOI":"10.3389\/fonc.2019.00939","article-title":"BCR-ABL Independent Mechanisms of Resistance in Chronic Myeloid Leukemia","volume":"9","author":"Loscocco","year":"2019","journal-title":"Front Oncol."},{"key":"10.1016\/j.bcp.2022.114964_b0045","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S1470-2045(03)00979-3","article-title":"Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias","volume":"4","author":"Gambacorti-Passerini","year":"2003","journal-title":"The lancet oncol."},{"key":"10.1016\/j.bcp.2022.114964_b0050","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.canlet.2015.02.026","article-title":"The role of heat shock proteins in cancer","volume":"360","author":"Lianos","year":"2015","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bcp.2022.114964_b0055","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.tips.2016.11.009","article-title":"Heat shock proteins and cancer","volume":"38","author":"Wu","year":"2017","journal-title":"Trend in Pharm. Sci."},{"key":"10.1016\/j.bcp.2022.114964_b0060","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1182\/blood-2013-01-479972","article-title":"Targeting the Hsp90-associated viral oncoproteome in gammaherpesvirus-associated malignancies","volume":"122","author":"Nayar","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2022.114964_b0065","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.tips.2014.09.001","article-title":"Selective targeting of the stress chaperome as a therapeutic strategy","volume":"35","author":"Taldone","year":"2014","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.bcp.2022.114964_b0070","doi-asserted-by":"crossref","first-page":"4731","DOI":"10.1158\/0008-5472.CAN-14-0747","article-title":"Hsp70-Bag3 interactions regulate cancer-related signaling networks","volume":"74","author":"Colvin","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2022.114964_b0075","doi-asserted-by":"crossref","first-page":"12900","DOI":"10.1074\/jbc.RA120.013364","article-title":"The chaperone Hsp70 is a BH3 receptor activated by the pro-apoptotic Bim to stabilize anti-apoptotic clients","volume":"295","author":"Guo","year":"2020","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2022.114964_b0080","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1038\/s41375-021-01283-5","article-title":"Small-molecule inhibitor targeting the Hsp70-Bim protein\u2013protein interaction in CML cells overcomes BCR-ABL-independent TKI resistance","volume":"35","author":"Song","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.bcp.2022.114964_b0085","first-page":"355ra117","article-title":"Combined targeting of bcl-2 and bcr-abl tyrosine kinase eradicates chronic myeloid leukemia stem cells","volume":"8","author":"Carter","year":"2006","journal-title":"Sci Transl Med."},{"key":"10.1016\/j.bcp.2022.114964_b0090","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.ccell.2020.03.006","article-title":"Response and Resistance to BCR-ABL1-Targeted Therapies","volume":"37","author":"Braun","year":"2020","journal-title":"Cancer Cell"},{"issue":"11","key":"10.1016\/j.bcp.2022.114964_b0095","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/s41580-019-0133-3","article-title":"The Hsp70 chaperone network","volume":"20","author":"Rosenzweig","year":"2019","journal-title":"Nat Rev Mol Cell Bio."},{"key":"10.1016\/j.bcp.2022.114964_b0100","doi-asserted-by":"crossref","first-page":"3948","DOI":"10.1182\/blood-2005-06-2209","article-title":"Ns-187, a potent and selective dual bcr-abl\/lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia","volume":"106","author":"Kimura","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2022.114964_b0105","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.chembiol.2014.09.001","article-title":"Small-Molecule Inhibitors of Protein-Protein Interactions: Progressing toward the Reality","volume":"21","author":"Arkin","year":"2014","journal-title":"Chem Biol."},{"key":"10.1016\/j.bcp.2022.114964_b0110","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.exphem.2009.10.005","article-title":"Effect of imatinib on the signal transduction cascade regulating telomerase activity in k562 (bcr-abl-positive) cells sensitive and resistant to imatinib","volume":"38","author":"Mor-Tzuntz","year":"2010","journal-title":"Exp Hematol."},{"key":"10.1016\/j.bcp.2022.114964_b0115","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1038\/leu.2011.285","article-title":"Activation of apoptosis signaling eliminates CD34+ progenitor cells in blast crisis CML independent of response to tyrosine kinase inhibitors","volume":"26","author":"Ma","year":"2012","journal-title":"Leukemia"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295222000582?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295222000582?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T15:14:34Z","timestamp":1762096474000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295222000582"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":23,"alternative-id":["S0006295222000582"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2022.114964","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bcr-Abl drives the formation of Hsp70\/Bim PPI to stabilize oncogenic clients and prevent cells from undergoing apoptosis","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2022.114964","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"114964"}}